Publication
Title
Tumour markers in metastatic colorectal cancer : clinical implications for treatment with targeted therapy
Author
Abstract
Targeted therapy with bevacuzimab, cetuximab and panitumumab has expanded the treatment options in metastatic colorectal cancer. Predictive tumour markers for treatment with targeted therapy that have been suggested are Epithelial Growth Factor Receptor (EGFR) and Vascular Endothelial Growth Factor Receptor (VEGFR) expression, KRAS mutation and BRAF mutation status, loss of PTEN and PIK3CA mutation status. Of these, only KRAS has made it into clinical practice. KRAS mutation is a negative predictor for response to cetuximab EGFR inhibitors. No predictive tumour marker for bevacizumab has been identified. In this review, the current evidence on KRAS, BRAF, PTEN, PIK3CA, EGFR and VEGFR expression as predictive tumour markers for targeted therapy is reviewed.
Language
English
Source (journal)
Belgian journal of medical oncology. - Amsterdam, 2007, currens
Publication
Amsterdam : 2012
ISSN
1784-7141
Volume/pages
6:2(2012), p. 52-57
Full text (publisher's version - intranet only)
UAntwerpen
Faculty/Department
Research group
Publication type
Subject
Affiliation
Publications with a UAntwerp address
External links
Record
Identification
Creation 19.05.2015
Last edited 02.10.2015
To cite this reference